Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Simple Summary Tamoxifen, aromatase inhibitors, and fulvestrant are the main drugs that
have been used for decades in the treatment of patients with endocrine-therapy-sensitive …

Endocrine therapy represents the gold standard for the adjuvant treatment of luminal-like
early breast cancer, but its personalization is still a major point of debate. To define the most …

For decades, mathematical models have influenced how we schedule chemotherapeutics.
More recently, mathematical models have leveraged lessons from ecology, evolution, and …

Simple Summary Five years of therapy remains the standard for adjuvant endocrine therapy
in early breast cancer. However, the recurrence risk remains elevated beyond this time …

Purpose: Strategies to implement estrogen therapy for advanced estrogen receptor–positive
(ER+) breast cancer are underdeveloped. Preclinical data suggest that cycling treatment …

Quantitative characterization of evolving tumor resistance under targeted treatment could
help identify novel treatment schedules, which may improve the outcome of anti-cancer …

Introduction Hormone therapy (HT) for breast cancer is associated with an increased risk of
venous thromboembolism (VTE). This study examines the effects of continuing versus …

In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant
endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the …

Purpose Vasomotor symptoms (VMS) are common among individuals with breast cancer
(BC) and poorly managed symptoms are associated with reduced quality of life, treatment …